864427-05-4 Usage
Uses
Used in Pharmaceutical Applications:
(Z)-2-hydroxy-4-oxo-4-(4-trifluoromethoxy-phenyl)-but-2-enoic acid ethyl ester is used as a pharmaceutical compound for its potential biological activity. The presence of various functional groups in its structure suggests that it may interact with biological targets, making it a candidate for the development of new drugs or therapeutic agents.
Used in Chemical Synthesis:
In the chemical industry, (Z)-2-hydroxy-4-oxo-4-(4-trifluoromethoxy-phenyl)-but-2-enoic acid ethyl ester can be used as a starting material or intermediate in the synthesis of other complex molecules. Its unique structure, including the trifluoromethoxy-phenyl group, may provide specific reactivity that can be exploited in the development of new chemical products.
Used in Material Science:
(Z)-2-hydroxy-4-oxo-4-(4-trifluoromethoxy-phenyl)-but-2-enoic acid ethyl ester's structure, which includes a hydroxy group and a trifluoromethoxy-phenyl group, may also make it suitable for use in material science applications. It could potentially be used to develop new materials with specific properties, such as improved stability, reactivity, or biocompatibility.
Check Digit Verification of cas no
The CAS Registry Mumber 864427-05-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,6,4,4,2 and 7 respectively; the second part has 2 digits, 0 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 864427-05:
(8*8)+(7*6)+(6*4)+(5*4)+(4*2)+(3*7)+(2*0)+(1*5)=184
184 % 10 = 4
So 864427-05-4 is a valid CAS Registry Number.
864427-05-4Relevant academic research and scientific papers
Pyrazole phenyl derivatives
-
Page/Page column 20, (2008/06/13)
The invention relates to compounds of the formula I: wherein one of R5, R6 and R7 is and X1, X2, R1 to R15 and n are as defined in the description, and pharmaceutically acceptabl
Indolyl derivatives
-
Page/Page column 21, (2010/02/14)
This invention relates to compounds of the formula I: wherein one of R6, R7 and R8 is and R1 to R15 and n are as defined in the description, and all enantiomers and pharmaceutically acceptable salts a
